Načítá se...
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
BACKGROUND: Gemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious. AIM: To evaluate a retrospective analysis comparing the efficacy and safety of FFX and...
Uloženo v:
| Vydáno v: | World J Clin Cases |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7479547/ https://ncbi.nlm.nih.gov/pubmed/32953848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i17.3718 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|